Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback